Health Policy Seminar
“Pharmaceutical Industry Payments to Primary Care Physicians: Differences in Trends and Effects on Prescribing by Physician Attributes”
Nathaniel Hendrix, PhD, PharmD, is a research scientist with the American Board of Family Medicine and their Center for Professionalism and Value in Health Care. His research focuses on pharmacoepidemiology, identification of heterogeneity in diagnostic and documentation practices, and natural language processing in primary care. Nathaniel holds a PharmD from the University of Washington School of Pharmacy, and a PhD from University of Washington’s Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, and was a Postdoctoral Research Fellow at Harvard University’s T.H. Chan School of Public Health from 2020 – 2022.
The pharmaceutical and device industries pay about $2 billion annually to physicians for non-research purposes. These payments vary dramatically by many factors, including specialty and gender, with men making 2- to 3-times as much as women in many specialties. One possible explanation for this difference is that industry targets physicians for payment who are more likely to change their prescribing patterns in favor of the drugs for which they receive payment. In this research, we combine payment data for several novel diabetes drugs with prescribing data from a large dataset of primary care electronic health records to examine how payment amount changes behavior among male versus female physicians and more versus less experienced physicians.
Date: Tuesday, June 17th
Time: 2:00pm – 3:00pm ET
Zoom Link: https://wellforce.zoom.us/j/97753510812?pwd=Ik9ez8bGecTPIhcEZfaSv2z7gA2ol9.1&from=addon
Passcode: 239862
